Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Radiopharm TheranosticsRDPTF Current Ratio is 2.67 as of Jun. 2025, which is 34% above its 10-year median of 1.99. The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Radiopharm Theranostics ranks worse than 60.24% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Radiopharm Theranostics's current ratio for the quarter that ended in Jun. 2025 was 2.67.
Radiopharm Theranostics has a current ratio of 2.67. It generally indicates good short-term financial strength.
The historical rank and industry rank for Radiopharm Theranostics's Current Ratio or its related term are showing as below:
RDPTF'
s Current Ratio Range Over the Past 10 Years
Min: 1.23 Med: 1.99 Max: 3.46
Current: 2.67
During the past 4 years, Radiopharm Theranostics's highest Current Ratio was 3.46. The lowest was 1.23. And the median was 1.99.
RDPTF's Current Ratio is ranked worse than 60.24% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs RDPTF: 2.67
Radiopharm Theranostics (OTCPK:RDPTF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Radiopharm Theranostics Current Ratio Related Terms
Radiopharm Theranostics Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDPTF vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics (RDPTF) has a Current Ratio of 2.67 as of Jun. 2025. This is 34% above median its historical median of 1.99. Over the past decade, Radiopharm Theranostics' Current Ratio has ranged from 1.23 to 3.46. According to the industry distribution chart, Radiopharm Theranostics ranks #850 out of 1411 companies in the Biotechnology industry, placing it in the top 60.2%.
Is Radiopharm Theranostics' Current Ratio too high?
Radiopharm Theranostics' current Current Ratio of 2.67 is 34% above median its 10-year median of 1.99. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 3.46. The Biotechnology industry median Current Ratio is 3.85. Radiopharm Theranostics' value of 2.67 is 30.6% below this industry median. Based on the distribution chart, Radiopharm Theranostics ranks #850 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint.
How does Radiopharm Theranostics' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #850 out of 1411 companies for Current Ratio. This places Radiopharm Theranostics in the lower half of its industry. The industry median Current Ratio is 3.85. Radiopharm Theranostics' value of 2.67 is 30.6% below this benchmark. Historically, Radiopharm Theranostics' own Current Ratio has ranged from 1.23 to 3.46 over the past decade. While the company's 10-year median is 1.99 vs. the industry median of 3.85, Radiopharm Theranostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radiopharm Theranostics's current Current Ratio of 2.67 is 30.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Current Ratio is 2.67, which is 34% above median its own 10-year median of 1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (RDPTF) has a current Current Ratio of 2.67. The current Current Ratio is 2.67, which is 34% above median its 10-year median of 1.99 and 30.6% below the Biotechnology industry median of 3.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Radiopharm Theranostics (RDPTF), the current Current Ratio is 2.67 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDPTF has been successfully added to your 
